{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:55:27Z","timestamp":1761807327472,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5977,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.nurt.2007.01.004","type":"journal-article","created":{"date-parts":[[2007,3,28]],"date-time":"2007-03-28T07:19:14Z","timestamp":1175066354000},"page":"199-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Challenges in the Design and Conduct of Therapeutic Trials in Channel Disorders"],"prefix":"10.1016","volume":"4","author":[{"given":"Shannon L.","family":"Venance","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara E.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Griggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2007.01.004_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-73-1-39","article-title":"Acetazolamide treatment of hypokalemic periodic paralysis","volume":"73","author":"Griggs","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nurt.2007.01.004_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/mus.880060303","article-title":"Treatment of \u201cpermanent\u201d muscle weakness in familial hypokalemic periodic paralysis","volume":"6","author":"Dalakas","year":"1983","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2007.01.004_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.nurt.2007.01.006","article-title":"Neurologic channelopothies: Evolving concepts and therapeutic challenges","volume":"4","author":"Tawil","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nurt.2007.01.015","article-title":"Physiologic principles underlying ion channelopothies","volume":"4","author":"Cannon","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/00019052-199410000-00010","article-title":"Developing new treatments for muscle disease: prospects and promise","volume":"7","author":"Griggs","year":"1994","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nurt.2007.01.004_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJMp058317","article-title":"Adopting orphan drugs--two dozen years of treating rare diseases","volume":"354","author":"Haffner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.01.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2006.01666.x","article-title":"A journey of hope: lessons learned from studies on rare diseases and orphan drugs","volume":"260","author":"Wastfelt","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.nurt.2007.01.004_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/brain\/awh639","article-title":"The primary periodic paralyses: diagnosis, pathogenesis and treatment","volume":"129","author":"Venance","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.nurt.2007.01.004_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11940-000-0022-1","article-title":"Channelopathies","volume":"2","author":"Moxley","year":"2000","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.nurt.2007.01.004_bib10","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMe030024","article-title":"Clinical trials and rare diseases","volume":"348","author":"Lagakos","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.01.004_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198604033141406","article-title":"Determining optimal therapy\u2014randomized trials in individual patients","volume":"314","author":"Guyatt","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.01.004_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/01.mph.0000212904.68899.1d","article-title":"N-of-1 trials: innovative methods to evaluate complementary and alternative medicines in pediatric cancer","volume":"28","author":"Sung","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.nurt.2007.01.004_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0895-4356(02)00537-1","article-title":"Comparative responsiveness of generic and specific quality-of-life instruments","volume":"56","author":"Wiebe","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nurt.2007.01.004_bib14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1531-8249(200001)47:1<46::AID-ANA9>3.0.CO;2-H","article-title":"Randomized trials of dichlorphenamide in the periodic paralyses","volume":"47","author":"Tawil","year":"2000","journal-title":"Ann Neurol"},{"issue":"suppl 10","key":"10.1016\/j.nurt.2007.01.004_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1528-1167.2005.00359.x","article-title":"Neonatal epilepsy syndromes and GEFS+: mechanistic considerations","volume":"46","author":"Burgess","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.nurt.2007.01.004_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.410420306","article-title":"Andersen\u2019s syndrome: a distinct periodic paralysis","volume":"42","author":"Sansone","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2007.01.004_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nurt.2007.01.005","article-title":"Management and treatment of Andersen-Tawil Syndrome (ATS)","volume":"4","author":"Sansone","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.WNL.0000101675.61074.50","article-title":"Clinical spectrum of episodic ataxia type 2","volume":"62","author":"Jen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.01.004_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nurt.2007.01.010","article-title":"Episodic ataxia type 1: Neuronal potassium channelopathy","volume":"4","author":"Rajakulendran","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nurt.2007.01.014","article-title":"Episodic ataxia type 2","volume":"4","author":"Strupp","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nurt.2007.01.009","article-title":"Channelopathies in idiopathic epilepsy","volume":"4","author":"Heron","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nurt.2007.01.007","article-title":"Autoimmune and paraneoplastic channelopathies","volume":"4","author":"Vernino","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrn1388","article-title":"Genetic mechanisms that underlie epilepsy","volume":"5","author":"Steinlein","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.nurt.2007.01.004_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.neuro.29.051605.112815","article-title":"Pathomechanisms in channelopathies of skeletal muscle and brain","volume":"29","author":"Cannon","year":"2006","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.nurt.2007.01.004_bib25","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1212\/01.WNL.0000143068.99794.5B","article-title":"SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide","volume":"63","author":"Venance","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.01.004_bib26","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1212\/01.WNL.0000145768.09934.EC","article-title":"New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis","volume":"63","author":"Vicart","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.01.004_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nurt.2007.01.001","article-title":"The therapy of congenital myasthenic syndromes","volume":"4","author":"Engel","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib28","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI25525","article-title":"Muscle channelopathies and critical points in functional and genetic studies","volume":"115","author":"Jurkat-Rott","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nurt.2007.01.004_bib29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.WNL.0000061483.11417.1B","article-title":"Treatment of slow-channel congenital myasthenic syndrome with fluoxetine","volume":"60","author":"Harper","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.01.004_bib30","unstructured":"Herr B, Kamp C, Trimble G, et al. Utility of electronic self-report tool to measure primary outcome in the HYP HOP study. Paper presented at: International Periodic Paralysis Meeting; October 2004; Rochester, NY."},{"key":"10.1016\/j.nurt.2007.01.004_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00004583-200206000-00005","article-title":"Anxiety, affect, and activity in teenagers: monitoring daily life with electronic diaries","volume":"41","author":"Henker","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.nurt.2007.01.004_bib32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00044067-200308000-00012","article-title":"The emerging role of electronic diaries in the management of diabetes mellitus","volume":"14","author":"Kerkenbush","year":"2003","journal-title":"AACN Clin Issues"},{"key":"10.1016\/j.nurt.2007.01.004_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0197-2456(02)00320-3","article-title":"Patient compliance with paper and electronic diaries","volume":"24","author":"Stone","year":"2003","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.nurt.2007.01.004_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0304-3959(85)90007-7","article-title":"Memory for pain: relation between past and present pain intensity","volume":"23","author":"Eich","year":"1985","journal-title":"Pain"},{"key":"10.1016\/j.nurt.2007.01.004_bib35","unstructured":"Herr BE, Malloy J, Cleland J, Krischer J. Automated tools for data collection and management in clinical research studies of Andersen-Tawil syndrome: improving protocol compliance and data quality. Paper presented at: National Leaders Forum; May 31\u2013June 1, 2006; Rockville, MD."},{"key":"10.1016\/j.nurt.2007.01.004_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nurt.2007.01.011","article-title":"Clinical evaluation of memebrane excitability in muscle channel disorders: Potential applications in clinical trials","volume":"4","author":"Cleland","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nurt.2007.01.004_bib37","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.20241","article-title":"Electromyography guides toward subgroups of mutations in muscle channelopathies","volume":"56","author":"Fournier","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2007.01.004_bib38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ana.20905","article-title":"Cold extends electromyography distinction between ion channel mutations causing myotonia","volume":"60","author":"Fournier","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2007.01.004_bib39","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","article-title":"Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine","volume":"62","author":"Strupp","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.01.004_bib40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajmg.1582","article-title":"Ion channels and epilepsy","volume":"106","author":"Lerche","year":"2001","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.nurt.2007.01.004_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2006.02.004","article-title":"Diverse mechanisms of antiepileptic drugs in the development pipeline","volume":"69","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.nurt.2007.01.004_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1096\/fj.03-0722fje","article-title":"Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats","volume":"18","author":"Tricarico","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.nurt.2007.01.004_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/mus.20585","article-title":"Acetazolamide acts directly on the human skeletal muscle chloride channel","volume":"34","author":"Eguchi","year":"2006","journal-title":"Muscle Nerve"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300658X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792300658X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2007.01.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:39:10Z","timestamp":1761806350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792300658X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S187874792300658X"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2007.01.004","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the Design and Conduct of Therapeutic Trials in Channel Disorders","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2007.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}